SCHEMBL2068641

SCHEMBL2068641

CCCOc1[c]nccc1C

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.33
NOS2 P35228 2/20 0.33
NPC1 O15118 2/20 0.33
HPGD P15428 2/20 0.33
RAB9A P51151 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
MAPK1 P28482 1/20 0.33
TLR8 Q9NR97 1/20 0.32
NOS3 P29474 1/20 0.32
ALDH1A1 P00352 2/20 0.31
LMNA P02545 1/20 0.31
HTT P42858 1/20 0.31
ATM Q13315 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
KDM4E B2RXH2 1/20 0.31
HSD17B10 Q99714 1/20 0.31
CACNA2D1 P54289 1/20 0.31
PTGS1 P23219 1/20 0.31
PTGS2 P35354 1/20 0.31
LTA4H P09960 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2066927 0.85 NQO1 (0.34) MAPTNOS2HPGDSMN1; SMN2NOS3
SCHEMBL2066408 0.84 TSHR (0.37) ALDH1A1HSD17B10
SCHEMBL3516824 0.80 MAPT (0.33) MAPTNPC1HPGDRAB9ASMN1; SMN2
SCHEMBL2066560 0.79 HPGD (0.39) MAPTNPC1HPGDRAB9ASMN1; SMN2
SCHEMBL2068079 0.79 TUBB4A (0.35) MAPTNPC1HPGDRAB9ASMN1; SMN2
SCHEMBL2066562 0.75 TLR8 (0.36) MAPTNPC1HPGDRAB9ASMN1; SMN2
SCHEMBL15414290 0.75 CYP17A1 (0.34) MAPTSMN1; SMN2ALDH1A1LMNATDP1
SCHEMBL2068081 0.75 TLR8 (0.36) MAPTNPC1RAB9ASMN1; SMN2TLR8
SCHEMBL2068642 0.74 TLR8 (0.38) MAPTNPC1HPGDRAB9ASMN1; SMN2
SCHEMBL1674701 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140005163-A1 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES NOVARTIS AG (CH) 2014-01-02 US disclosed
US-8476294-B2 1H-imidazo[4,5-c]quinolinone derivatives NOVARTIS AG (CH) 2013-07-02 US disclosed
EP-2438064-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES Novartis AG (CH) 2012-04-11 EP disclosed
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG 2010-12-16 US disclosed
WO-2010139731-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES NOVARTIS AG (CH) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317657-A1 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES PRKCA, CSNK1A1, ABL1 MAPT 1751/4885NOS2 3170/4885NPC1 412/4885
US-20140005163-A1 1H-IMIDAZO[4,5-C]QUINOLINONE DERIVATIVES PRKCA, CSNK1A1, ABL1 MAPT 1751/4885NOS2 3170/4885NPC1 412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.